Search

Your search keyword '"Suárez Álvarez, Patricia"' showing total 5 results
Start Over Author "Suárez Álvarez, Patricia" Language english
5 results on '"Suárez Álvarez, Patricia"'

1. Persistence, effectiveness and safety of ustekinumab and vedolizumab therapy for complex perianal fistula in Crohn's disease: The HEAL study from GETECCU

Author

Casanova, María José, Caballol, Berta, García, María José, Mesonero, Francisco, Rubín de Célix, Cristina, Suárez-Álvarez, Patricia, Ferreiro-Iglesias, Rocío, Martín-Rodríguez, María del Mar, de Francisco, Ruth, Varela-Trastoy, Pilar, Bastida, Guillermo, Carrillo-Palau, Marta, Núñez-Ortiz, Andrea, Ramírez-de la Piscina, Patricia, Ceballos, Daniel, Hervías-Cruz, Daniel, Muñoz-Pérez, Roser, Velayos, Benito, Bermejo, Fernando, Busquets, David, Cabacino, Manuel, Camo-Monterde, Patricia, Marín-Jiménez, Ignacio, Muñoz, Carmen, de la Peña-Negro, Luisa Carmen, Sierra-Moros, Eva, Barrio, Jesús, Brunet-Mas, Eduard, Bujanda, Luis, Cañete, Fiorella, Gomollón, Fernando, Manceñido-Marcos, Noemí, Rodríguez-Lago, Iago, Rodríguez-Grau, María Carmen, Sicilia, Beatriz, Torra-Alsina, Sandra, Arranz-Hernández, Laura, Carpio, Daniel, García-Sepulcre, Mariana Fe, González-Muñoza, Carlos, Huguet, José María, Márquez-Mosquera, Lucía, López-Serrano, María Pilar, Ponferrada-Díaz, Ángel, Chaparro, María, and Gisbert, Javier P.

Published
2024
Full Text
View/download PDF

3. 36 - EFECTIVIDAD Y SEGURIDAD DE LA TERAPIA CON USTEKINUMAB Y VEDOLIZUMAB EN PACIENTES CON FÍSTULA PERIANAL COMPLEJA: ESTUDIO HEAL

Author

Casanova, María José, Chaparro, María, Caballol, Berta, García, María José, Mesonero, Francisco, de Célix, Cristina Rubín, Suárez-álvarez, Patricia, Ferreiro-Iglesias, Rocío, del Mar Martín-Rodríguez, María, de Francisco, Ruth, Varela-Trastoy, Pilar, Bastida, Guillermo, Carrillo-Palau, Marta, Núñez-Ortiz, Andrea, Piscina, Patricia Ramírez-de la, Ceballos, Daniel, Hervías-Cruz, Daniel, Muñoz-Pérez, Roser, Velayos, Benito, Bermejo, Fernando, Busquets, David, Cabacino, Manuel, Camo-Monteverde, Patricia, Marín-Jiménez, Ignacio, Muñoz, Carmen, de la Peña-Negro, Luisa Carmen, Sierra-Moros, Eva, Barrio, Jesús, Brunet-Mas, Eduard, Bujanda, Luis, Cañete, Fiorella, Gomollón, Fernando, Manceñido-Marcos, Noemí, Rodríguez-Lago, Iago, Rodríguez-Grau, María Carmen, Sicilia, Beatriz, Torra-Alsina, Sandra, Arranz-Hernández, Laura, Carpio, Daniel, García-Sepulcre, Mariana Fe, González-Muñoza, Carlos, Huguet, José María, Márquez-Mosquera, Lucía, López-Serrano, María Pilar, Ponferrada-Díaz, Ángel, and Gisbert, Javier P.

Published
2023
Full Text
View/download PDF

4. Effectiveness and Safety of Ustekinumab in Ulcerative Colitis: Real-world Evidence from the ENEIDA Registry.

Author

Chaparro M, Garre A, Iborra M, Sierra-Ausín M, Barreiro-de Acosta M, Fernández-Clotet A, de Castro L, Boscá-Watts M, Casanova MJ, López-García A, Lorente R, Rodríguez C, Carbajo AY, Arroyo MT, Gutiérrez A, Hinojosa J, Martínez-Pérez T, Villoria A, Bermejo F, Busquets D, Camps B, Cañete F, Manceñido N, Monfort D, Navarro-Llavat M, Pérez-Calle JL, Ramos L, Rivero M, Angueira T, Camo Monterde P, Carpio D, García-de-la-Filia I, González-Muñoza C, Hernández L, Huguet JM, Morales VJ, Sicilia B, Vega P, Vera I, Zabana Y, Nos P, Suárez Álvarez P, Calviño-Suárez C, Ricart E, Hernández V, Mínguez M, Márquez L, Hervías Cruz D, Rubio Iturria S, Barrio J, Gargallo-Puyuelo C, Francés R, Hinojosa E, Del Moral M, Calvet X, Algaba A, Aldeguer X, Guardiola J, Mañosa M, Pajares R, Piqueras M, García-Bosch O, López Serrano P, Castro B, Lucendo AJ, Montoro M, Castro Ortiz E, Mesonero F, García-Planella E, Fuentes DA, Bort I, Delgado-Guillena P, Arias L, Iglesias A, Calvo M, Esteve M, Domènech E, and Gisbert JP

Subjects
Female, Humans, Infusions, Intravenous, Male, Middle Aged, Prospective Studies, Registries, Remission Induction, Ustekinumab administration & dosage, Colitis, Ulcerative drug therapy, Ustekinumab therapeutic use
Abstract

Background and Aims: The development programm UNIFI has shown promising results of ustekinumab in ulcerative colitis [UC] treatment which should be confirmed in clinical practice. We aimed to evaluate the durability, effectiveness, and safety of ustekinumab in UC in real life., Methods: Patients included in the prospectively maintained ENEIDA registry, who received at least one intravenous dose of ustekinumab due to active UC [Partial Mayo Score [PMS]>2], were included. Clinical activity and effectiveness were defined based on PMS. Short-term response was assessed at Week 16., Results: A total of 95 patients were included. At Week 16, 53% of patients had response [including 35% of patients in remission]. In the multivariate analysis, elevated serum C-reactive protein was the only variable significantly associated with lower likelihood of achieving remission. Remission was achieved in 39% and 33% of patients at Weeks 24 and 52, respectively; 36% of patients discontinued the treatment with ustekinumab during a median follow-up of 31 weeks. The probability of maintaining ustekinumab treatment was 87% at Week 16, 63% at Week 56, and 59% at Week 72; primary failure was the main reason for ustekinumab discontinuation. No variable was associated with risk of discontinuation. Three patients reported adverse events; one of them had a fatal severe SARS-CoV-2 infection., Conclusions: Ustekinumab is effective in both the short and the long term in real life, even in a highly refractory cohort. Higher inflammatory burden at baseline correlated with lower probability of achieving remission. Safety was consistent with the known profile of ustekinumab., (© The Author(s) 2021. Published by Oxford University Press on behalf of European Crohn’s and Colitis Organisation. All rights reserved. For permissions, please email: journals.permissions@oup.com.)

Published
2021
Full Text
View/download PDF

5. Serrated Lesions in patients with Inflammatory Bowel Disease.

Author

Viso Vidal D, Sierra Ausín M, Suárez Álvarez P, and Jorquera Plaza F

Subjects
Humans, Male, Middle Aged, Inflammatory Bowel Diseases pathology
Abstract

Background: a new serrated histologic finding has recently been discovered in patients with inflammatory bowel disease (IBD), known as serrated epithelial change (SEC). Recent studies suggest that SEC is strongly associated with dysplasia., Case Report: the case was a 62-year-old male in a dysplasia-colorectal cancer screening program with periodic chromoendoscopies, with CES findings in the previous chromoendoscopy studies., Discussion: a prophylactic colectomy seems a reasonable option for patients with several serrated lesions identified via chromoendoscopy screening. Particularly, if they are extensive and poorly defined, due to the possibility of developing high-grade dysplasia or colorectal cancer (CRC) during surveillance.

Published
2019
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results